(December 4, 2017, 1:26 PM EST) -- WASHINGTON, D.C. — The U.S. Supreme Court on Dec. 4 invited the U.S. solicitor general to express the views of the United States on whether there is “clear and convincing evidence” that the Food and Drug Administration would have rejected a stronger warning about femur fractures from the osteoporosis drug Fosamax (Merck Sharpe & Dohme Corp. v. Doris Albrecht, et al., No. 17-290, U.S. Sup.)....